• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

A Novel Bispecific Anti-GPRC5D × CD3 Antibody: A New Treatment Paradigm in Multiple Myeloma

by | May 21, 2024 | Myeloma News

Source: Pharmacy Times articles Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach. Read More

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

by | May 17, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

by | May 16, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes

by | May 16, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Enhancing diagnostic accuracy of multiple myeloma through ML-driven analysis of hematological slides: new dataset and identification model to support hematologists

by | May 16, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

by | May 9, 2024 | Myeloma News

Source: Pharmacy Times articles Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • CAR-T cell therapy in Multiple Myeloma: current status and future challenges
  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT